Prevalence of Osteoporosis in Sickle Cell Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04299594

Acronym

DREPAN'OS

Enrollment

142

Registered

2020-03-09

Start date

2020-06-18

Completion date

2021-12-18

Last updated

2023-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sickle Cell Disease

Keywords

sickle cell disease

Brief summary

Sickle cell disease is the most common single-gene disease in the world. Its prevalence is increasing in France, with patients' life expectancy increasing into developed countries. It mainly affects populations originating from sub-Saharan Africa. Among the chronic bone complications associated with sickle cell disease, osteoporosis has previously been highlighted but remains a poorly known complication in this very particular context. A dedicated evaluation of osteoporosis and associated risk factors in sickle cell disease patients living in France may enable better bone management of these patients in the future, as this problem, specific to their disease, is likely to become more frequent as their life expectancy increases. This is a prospective interventional and monocentric study whose objective is to describe the prevalence of osteoporosis in black patients with sickle cell disease in France

Interventions

OTHERQuestionnaire

For each subject recruited, will be collected for the study a questionnaire looking for a history of low energy fracture, and the origins of the patient (or relatives), as well as medical history, lifestyle (alcohol and tobacco consumption), weight and height. This data will be used for the secondary outcomes.

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 40 Years

Healthy volunteers

Inclusion criteria

* Black-skinned men and women * Aged 20 to 40 years old * Sickle cell patients * Non-opposition to participate in the study

Exclusion criteria

* Refusal to participate in the study * Hemoglobinopathy other than sickle cell disease * Severe or End Stage Renal Failure * Long-term corticosteroid therapy (\>3 months) * History of solid cancer or malignant haemopathy * History of organ transplantation * Pregnant or breastfeeding woman * Psychiatric pathology seriously impeding understanding * Difficulty understanding oral French

Design outcomes

Primary

Measure	Time frame	Description
Bone mineral density	Day 1	Bone mineral density is measured by systematic bone densitometry at 3 sites: lumbar spine, femoral neck and total hip. These data will be collected in the patient's medical record

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026